EGRX Eagle Pharmaceuticals Inc

Price (delayed)

$4.76

Market cap

$61.82M

P/E Ratio

5.17

Dividend/share

N/A

EPS

$0.92

Enterprise value

$116.66M

Eagle Pharmaceuticals Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements ...

Highlights
Eagle Pharmaceuticals's quick ratio has increased by 35% YoY and by 8% from the previous quarter
The company's equity rose by 6% YoY and by 3.8% QoQ
Eagle Pharmaceuticals's debt has increased by 41% YoY but it has decreased by 8% QoQ
Eagle Pharmaceuticals's gross margin has decreased by 5% YoY but it has increased by 2% from the previous quarter
The EPS has contracted by 50% YoY
The net income has declined by 48% year-on-year

Key stats

What are the main financial stats of EGRX
Market
Shares outstanding
12.99M
Market cap
$61.82M
Enterprise value
$116.66M
Valuations
Price to earnings (P/E)
5.17
Price to book (P/B)
0.25
Price to sales (P/S)
0.24
EV/EBIT
3.31
EV/EBITDA
2.04
EV/Sales
0.45
Earnings
Revenue
$257.55M
EBIT
$35.26M
EBITDA
$57.18M
Free cash flow
-$9.39M
Per share
EPS
$0.92
Free cash flow per share
-$0.72
Book value per share
$19.25
Revenue per share
$19.67
TBVPS
$19.28
Balance sheet
Total assets
$404.82M
Total liabilities
$152.78M
Debt
$70.19M
Equity
$252.04M
Working capital
$100.62M
Liquidity
Debt to equity
0.28
Current ratio
2.16
Quick ratio
1.51
Net debt/EBITDA
0.96
Margins
EBITDA margin
22.2%
Gross margin
69.8%
Net margin
4.6%
Operating margin
15.9%
Efficiency
Return on assets
3%
Return on equity
5%
Return on invested capital
19.3%
Return on capital employed
11.1%
Return on sales
13.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EGRX stock price

How has the Eagle Pharmaceuticals stock price performed over time
Intraday
0.21%
1 week
4.85%
1 month
8.43%
1 year
-76.38%
YTD
-8.99%
QTD
-9.16%

Financial performance

How have Eagle Pharmaceuticals's revenue and profit performed over time
Revenue
$257.55M
Gross profit
$179.88M
Operating income
$41.01M
Net income
$11.95M
Gross margin
69.8%
Net margin
4.6%
The net income has declined by 48% year-on-year
Eagle Pharmaceuticals's net margin has decreased by 45% YoY
The operating margin is up by 29% since the previous quarter but it has declined by 25% year-on-year
Eagle Pharmaceuticals's operating income has decreased by 29% YoY but it has increased by 25% QoQ

Growth

What is Eagle Pharmaceuticals's growth rate over time

Valuation

What is Eagle Pharmaceuticals stock price valuation
P/E
5.17
P/B
0.25
P/S
0.24
EV/EBIT
3.31
EV/EBITDA
2.04
EV/Sales
0.45
The EPS has contracted by 50% YoY
EGRX's P/B is 92% below its 5-year quarterly average of 3.0 and 82% below its last 4 quarters average of 1.4
The company's equity rose by 6% YoY and by 3.8% QoQ
EGRX's price to sales (P/S) is 91% lower than its 5-year quarterly average of 2.8 and 80% lower than its last 4 quarters average of 1.2
The company's revenue fell by 5% YoY and by 3.6% QoQ

Efficiency

How efficient is Eagle Pharmaceuticals business performance
The ROS has soared by 90% from the previous quarter but it has contracted by 12% YoY
EGRX's return on invested capital has surged by 61% since the previous quarter but it has dropped by 55% year-on-year
Eagle Pharmaceuticals's ROA has plunged by 60% YoY
Eagle Pharmaceuticals's return on equity has shrunk by 55% YoY

Dividends

What is EGRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EGRX.

Financial health

How did Eagle Pharmaceuticals financials performed over time
Eagle Pharmaceuticals's total assets is 165% higher than its total liabilities
Eagle Pharmaceuticals's quick ratio has increased by 35% YoY and by 8% from the previous quarter
EGRX's current ratio is up by 21% YoY and by 10% QoQ
Eagle Pharmaceuticals's debt is 72% lower than its equity
Eagle Pharmaceuticals's debt has increased by 41% YoY but it has decreased by 8% QoQ
Eagle Pharmaceuticals's debt to equity has increased by 33% YoY but it has decreased by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.